reach semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or The Ozempic Pill Has Arrived.

And theres most people are in the middle

However, for most people with normal B12 levels, supplementation or injections do not significantly affect metabolism or fat loss

Given the potential for long-term GLP-1 therapy for weight loss and diabetes, we want to avoid anything that could lead to dependence

Most of the clinical use of CJC-1295 is extrapolated from these smaller studies and mechanistic reasoning from GHRH physiology

Whilst there may be complex interactions between metabolic signalling and classical neurotransmitter pathways, these connections are indirect and multifaceted rather than straightforward cause-and-effect relationships

This optimized configuration was used in all further experiments